Sekhmet Pharmaventures Private Limited agreed to acquire 19.97% stake in Optimus Drugs Private Limited for INR 2.7 billion on May 10, 2022. As per terms the acquisition company proposes to sell its entire shareholding in Optimus to the Purchaser by secondary transfer of shares in two tranches. As of Optimus Drugs Private Limited reported a turnover of approximately INR 10 billion. the transaction is subject to approval of Competition Commission of India. Jayendra Shah of Transcontinental Capital Advisors acted as transaction advisor, N.A. Shah Advisory Services LLP acted as financial and tax advisors and Khaitan & Co. acted as legal advisors to the promoters in the transaction. Bharat Budholia, Ashwath Rau, Kashish Bhatia and Atreya Bhattacharya of AZB & Partners acted as legal advisors to PAG, CX Partners, Samara Capital and Sekhmet Pharmaventures. Citadel Management Consulting acted as Financial advisor to PAG, CX Partners and Samara Capital. Ernst & Young acted as financial advisor to PAG. PricewaterhouseCoopers acted as accountant and provided tax due diligence to PAG. Bhavik Narsana, Vidur Sinha, Anisha Chand, Nishad Nadkarni and Deepak Kumar of Khaitan & Co. acted as a legal advisor to Optimus Drugs Private Limited. As of August 12, 2022, Competition Commission of India (CCI) approves acquisition of majority shareholding in Optimus Drugs Private Limited (ODPL) by Sekhmet Pharmaventures Private Limited, ultimately belongs to the PAG group.

Sekhmet Pharmaventures Private Limited acquired 19.97% stake in Optimus Drugs Private Limited in March, 2023.